Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

Journal Scan / Research · April 10, 2024

Pembrolizumab With Chemoradiotherapy Followed by Pembrolizumab for Newly Diagnosed, High-Risk, Locally Advanced Cervical Cancer

The Lancet


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial
Lancet 2024 Apr 06;403(10434)1341-1350, D Lorusso, Y Xiang, K Hasegawa, G Scambia, M Leiva, P Ramos-Elias, A Acevedo, V Sukhin, N Cloven, AJ Pereira de Santana Gomes, F Contreras Mejía, A Reiss, A Ayhan, JY Lee, V Saevets, F Zagouri, L Gilbert, J Sehouli, E Tharavichitkul, K Lindemann, R Lazzari, CL Chang, R Lampé, H Zhu, A Oaknin, M Christiaens, S Polterauer, T Usami, K Li, K Yamada, S Toker, SM Keefe, S Pignata, LR Duska

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading